DK2782566T3 - L-serin til anvendelse ved behandling af neurodegenerative lidelser - Google Patents
L-serin til anvendelse ved behandling af neurodegenerative lidelser Download PDFInfo
- Publication number
- DK2782566T3 DK2782566T3 DK12851576.4T DK12851576T DK2782566T3 DK 2782566 T3 DK2782566 T3 DK 2782566T3 DK 12851576 T DK12851576 T DK 12851576T DK 2782566 T3 DK2782566 T3 DK 2782566T3
- Authority
- DK
- Denmark
- Prior art keywords
- serin
- treatment
- neurodegenerative disorders
- neurodegenerative
- disorders
- Prior art date
Links
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562194P | 2011-11-21 | 2011-11-21 | |
| PCT/US2012/066373 WO2013078395A1 (en) | 2011-11-21 | 2012-11-21 | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2782566T3 true DK2782566T3 (da) | 2021-02-08 |
Family
ID=48470319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12851576.4T DK2782566T3 (da) | 2011-11-21 | 2012-11-21 | L-serin til anvendelse ved behandling af neurodegenerative lidelser |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20130156846A1 (da) |
| EP (1) | EP2782566B1 (da) |
| JP (1) | JP6265908B2 (da) |
| AU (1) | AU2012340563B2 (da) |
| CA (1) | CA2855854C (da) |
| DK (1) | DK2782566T3 (da) |
| ES (1) | ES2856063T3 (da) |
| IL (1) | IL232710B (da) |
| PT (1) | PT2782566T (da) |
| WO (1) | WO2013078395A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3459540A1 (en) * | 2014-11-24 | 2019-03-27 | Entrinsic Health Solutions, Inc. | Amino acid compositions for the treatment of symptoms of disease |
| US10960076B2 (en) | 2017-01-25 | 2021-03-30 | Church & Dwight Co. Inc. | Gummy dosage forms comprising serine |
| KR20180101242A (ko) | 2017-03-02 | 2018-09-12 | 주식회사 아스트로젠 | 엘세린을 유효성분으로 포함하는 혈뇌장벽 장애의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| EP3801487A4 (en) * | 2018-06-08 | 2022-03-30 | The Institute for Ethnomedicine | METHOD OF IMPROVING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM |
| KR101952443B1 (ko) * | 2018-08-23 | 2019-02-26 | 주식회사 아스트로젠 | 신규한 마그네슘세리네이트 화합물 및 이의 용도 |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| EP4017278A4 (en) * | 2019-08-21 | 2023-09-13 | Brain Chemistry Labs | METAL AND L-SERINE COMPOSITIONS AND USES THEREOF |
| US20220252620A1 (en) * | 2021-02-05 | 2022-08-11 | The Institute for Ethnomedicine dba Brain Chemistry Labs | Blood indicators of alzheimer's disease |
| CN112972458B (zh) * | 2021-03-05 | 2022-10-04 | 北京北科华夏生物医药科技有限公司 | 一种组合物在制备阿尔兹海默症治疗药物中的应用 |
| KR102522508B1 (ko) * | 2022-12-16 | 2023-04-18 | 주식회사 아스트로젠 | 마그네슘-세리네이트의 신규한 결정형 및 이의 제조방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873722A (en) | 1974-05-31 | 1975-03-25 | Nelson Res & Dev | Method for treating schizophrenia |
| US4000318A (en) * | 1974-08-19 | 1976-12-28 | Commonwealth Scientific And Industrial Research Organization | Amino acid supplements |
| US4491589A (en) * | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| JPS6440453A (en) | 1987-08-05 | 1989-02-10 | Mitsui Toatsu Chemicals | Racemization of optically active serine |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| SE502280C2 (sv) | 1991-12-20 | 1995-09-25 | Bio Swede Ab | Separering av aminosyror, aminosyrabaserad monomer och förfarande för framställning därav samt polymert material och förfarande för framställning därav |
| WO1996015788A1 (en) | 1994-11-23 | 1996-05-30 | G.D. Searle & Co. | Use of amino-isoxazolidone compounds for improvement of implicit memory |
| CA2298795A1 (en) * | 1997-07-28 | 1999-02-04 | The Institute Of Physical And Chemical Research | Agent for protecting central nerve cells and enhancing survival thereof |
| EP2338482A3 (en) | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| US6984484B1 (en) * | 1999-01-19 | 2006-01-10 | The Johns Hopkins University | Mammalian serine racemase |
| JP2002316929A (ja) * | 2001-04-18 | 2002-10-31 | Japan Science & Technology Corp | Ｌ−セリン又はグリシンからなる抗アポトーシス剤 |
| ATE457726T1 (de) * | 2002-06-19 | 2010-03-15 | Nutricia Nv | Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen |
| JP2004182705A (ja) * | 2002-10-11 | 2004-07-02 | Yasutoshi Koga | ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物 |
| US20050028720A1 (en) * | 2003-08-05 | 2005-02-10 | Bell Adam Warwick | Pop-up device for deterring an attacking animal such as a bear |
| AU2003296424A1 (en) * | 2003-08-12 | 2005-03-10 | Institute For Ethnomedicine | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders |
| US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| FI121915B (fi) | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Koostumus psoriasiksen hoitoon |
| CA2560920A1 (en) | 2004-03-26 | 2005-10-06 | Warner-Lambert Company Llc | Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia |
| EP1799217A4 (en) | 2004-10-12 | 2008-01-23 | Forbes Medi Tech Res Inc | Compositions and methods for treating insulin resistance and cardiomyopathy |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| WO2008118785A2 (en) | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
| US20080241121A1 (en) | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| EP2313776B1 (en) * | 2008-07-09 | 2013-10-30 | The Institute for Ethnomedicine | Immunoassay for detection of neurotoxic amino acid associated with neurological disorders |
| US9072730B2 (en) * | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| WO2011104298A1 (en) * | 2010-02-24 | 2011-09-01 | Universität Zürich | Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
-
2012
- 2012-11-21 CA CA2855854A patent/CA2855854C/en active Active
- 2012-11-21 AU AU2012340563A patent/AU2012340563B2/en active Active
- 2012-11-21 US US13/683,821 patent/US20130156846A1/en not_active Abandoned
- 2012-11-21 WO PCT/US2012/066373 patent/WO2013078395A1/en active Application Filing
- 2012-11-21 PT PT128515764T patent/PT2782566T/pt unknown
- 2012-11-21 ES ES12851576T patent/ES2856063T3/es active Active
- 2012-11-21 JP JP2014543579A patent/JP6265908B2/ja active Active
- 2012-11-21 DK DK12851576.4T patent/DK2782566T3/da active
- 2012-11-21 EP EP12851576.4A patent/EP2782566B1/en active Active
-
2014
- 2014-03-28 US US14/229,624 patent/US11917986B2/en active Active
- 2014-05-20 IL IL232710A patent/IL232710B/en unknown
-
2017
- 2017-10-06 US US15/727,335 patent/US11700840B2/en active Active
-
2021
- 2021-02-02 US US17/165,897 patent/US20210153483A1/en active Pending
- 2021-07-12 US US17/373,434 patent/US11974551B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL232710B (en) | 2021-12-01 |
| US20220000082A1 (en) | 2022-01-06 |
| CA2855854A1 (en) | 2013-05-30 |
| EP2782566A1 (en) | 2014-10-01 |
| EP2782566A4 (en) | 2016-01-13 |
| US20180027781A1 (en) | 2018-02-01 |
| AU2012340563B2 (en) | 2017-01-19 |
| US11974551B2 (en) | 2024-05-07 |
| EP2782566B1 (en) | 2021-01-06 |
| US11917986B2 (en) | 2024-03-05 |
| US20140212893A1 (en) | 2014-07-31 |
| JP6265908B2 (ja) | 2018-01-24 |
| US20130156846A1 (en) | 2013-06-20 |
| US20210153483A1 (en) | 2021-05-27 |
| IL232710A0 (en) | 2014-07-31 |
| ES2856063T3 (es) | 2021-09-27 |
| JP2014534263A (ja) | 2014-12-18 |
| PT2782566T (pt) | 2021-03-03 |
| WO2013078395A1 (en) | 2013-05-30 |
| US11700840B2 (en) | 2023-07-18 |
| CA2855854C (en) | 2020-03-31 |
| AU2012340563A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK3321276T3 (da) | Fusionsproteiner til behandling af metaboliske lidelser | |
| DK2782566T3 (da) | L-serin til anvendelse ved behandling af neurodegenerative lidelser | |
| DK3305317T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
| DK2838539T3 (da) | Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| DK2522342T3 (da) | Topisk formulering til behandling af hyperkeratonisk hud | |
| DK2838907T3 (da) | Aminosteroider til behandlingen af en ptp1b-associeret sygdom | |
| DK2822558T3 (da) | Procaspase 3 aktivering ved hjælp af kombinations terapi | |
| DK2705886T3 (da) | Filtermekanisme | |
| DK2906219T3 (da) | Orvepitant til behandling af kronisk pruritus | |
| BR112014004416A2 (pt) | composições e métodos para o tratamento de doenças neurodegenerativas | |
| DK2830645T3 (da) | Neuregulin til anvendelse i behandling af perifær nervelæsion | |
| DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| DK2892556T3 (da) | Sammensætninger og fremgangsmåder til behandling af sygdomme | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi |